Dennis J. Slamon, MD, PhD, Kathleen I. Pritchard, MD, FRCPC, and Stephen E. Jones, MD, discuss recent clinical trial results and the prognostic implications of changes in HER2 and topoisomerase IIα expression for making treatment choices on the use of anthracycline- vs nonanthracycline-containing regimens to treat patients with early breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss clinical trial results using anthracycline-containing regimens vs nonanthracycline-containing regimens
- Describe data supporting the role of HER2 and topoisomerase IIα as predictors of anthracycline-sensitivity in early breast cancer patients
- Cite the historical status of anthracycline treatment as a standard of care for early breast cancer
- Summarize the adverse events associated with anthracycline-containing regimens